结节性痒疹治疗市场（按产品、通路和地区划分）2024 年至 2031 年

结节性痒疹治疗市场评估 - 2024 - 2031

由于结节性痒疹 (PN) 盛行率不断上升以及医疗专业人员和患者意识的提高，结节性痒疹 (PN) 治疗市场正在发展。结节性痒疹是一种持续性皮肤病，会引起搔痒性结节并严重影响患者的生活品质。过去十年，由于诊断程序的改进以及皮肤科医生和全科医生对该疾病的认识的提高，确诊病例数不断增加，预计到 2024 年该市场的销售额将超过 13 亿美元，到 2031 年估值将达到约 19 亿美元。

远距医疗和数位健康平台的日益普及使得皮肤科咨询和治疗变得更加容易，从而促进了 PN 治疗的需求不断增长。因此，由于患病率上升、治疗方法改善以及患者获得医疗服务的管道改善等多种因素，PN 治疗市场预计将大幅增长，预计 2024 年至 2031 年期间的复合年增长率为 5.30%。

结节性痒疹治疗市场定义/概述

结节性痒疹 (PN) 是一种慢性皮肤病，其特征是由于持续抓挠和发炎而导致频繁出现高度刺激性的结节。结节性痒疹的治疗重点在于缓解症状、控制搔痒和解决根本原因，以改善患者的生活品质。局部治疗是治疗结节性痒疹最常见的方法之一。皮质类固醇、钙调神经磷酸酶抑制剂和辣椒素洗剂常用于治疗发炎和搔痒。

结节性痒疹 (PN) 是一种持续性皮肤病，会引起搔痒性结节并严重影响患者的生活品质。结节性痒疹的治疗方法多种多样，主要集中在症状管理、缓解搔痒和改善皮肤病变。局部治疗是治疗结节性痒疹最常见的适应症之一。这些包括皮质类固醇、钙调神经磷酸酶抑制剂和辣椒素乳膏。

PN 管理的未来可能需要结合药物学和非药物学技术的综合方法。随着有关 PN 心理影响的文献越来越多，包括行为疗法、压力管理和生活方式改变在内的综合治疗策略正变得越来越被广泛接受。

辣椒素霜需求的增加会影响产品细分市场吗？

对辣椒素乳膏的需求不断增加是结节性痒疹治疗市场的主要驱动力，尤其是在产品领域。辣椒素是从辣椒中提取出来的，有望用于治疗结节性痒疹引起的剧烈瘙痒。结节性痒疹的盛行率不断上升是推动这项需求的主要原因。根据美国皮肤病学会杂誌发表的一项研究，美国结节性痒疹的盛行率估计为每十万人中有72例。这意味着仅在美国就有大约 23 万人患有这种疾病。根据国家湿疹协会的数据，PN 影响着普通社区中每 4,000 人中的 1 人，显示其流行范围十分广泛。

根据美国国家生物技术资讯中心 (NCBI) 的数据，在临床试验中，33% 使用辣椒素乳膏的患者报告瘙痒症状明显减少，而使用安慰剂的患者只有 7%。这表明辣椒素可能有助于治疗 PN 症状。此外，人们对天然和非处方药物的兴趣日益浓厚，这也推动了辣椒素乳膏市场的发展。美国皮肤病学会指出，外用辣椒素无需处方即可获得，这对许多人来说是一种可行的选择。

合格医疗保健专业人员的短缺是否会阻碍结节性痒疹治疗市场的发展？

结节性痒疹治疗市场可能会因熟练医疗保健人员的短缺而受到阻碍，儘管各种因素可能会减轻这一潜在障碍。一个主要的促成因素是全球结节性痒疹（PN）的盛行率不断增加。儘管由于诊断不足，确切数字有限，但研究表明，在美国每 10 万人中约有 72 人患有 PN。频率的增加促使对治疗方案和专家的需求增加。此外，诊断方法的进步使得识别 PN 患者变得更加容易。例如，2022 年《美国皮肤病学会杂誌》上发表的一项研究发现，与单纯的临床检测相比，皮肤镜检查使 PN 诊断的准确率提高了 23%。

预计这一巨大的经济影响将刺激对治疗开发和专业培训的投资。此外，FDA 于 2022 年批准 dupilumab 用于治疗 PN，这也增加了人们对该市场领域的认识和兴趣。据美国国家湿疹协会称，dupilumab 在临床试验中将搔痒强度降低了 60%，并有可能改善许多 PN 患者的生活品质。儘管医疗人才短缺仍然是一个问题，但有几个市场因素可能有助于抵消其影响。儘管面临劳动力课题，但疾病意识的提高、经济激励和治疗方法的改善应该会吸引更多的专家进入该领域，并有助于推动市场扩张。然而，要充分发挥市场的潜力，必须解决医疗人才短缺的问题。

目录

第 1 章 全球结节性痒疹治疗市场简介

• 市场概况
• 研究范围
• 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

• 资料探勘
• 验证
• 主要来源
• 资料来源列表

第 4 章全球结节性痒疹治疗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

第5章全球结节性痒疹治疗市场（按产品）

• 概述
• 抗组织胺药
• 辣椒素霜
• 皮质类固醇
• 润肤剂
• 其他

第6章全球结节性痒疹治疗市场（依通路）

• 概述
• 零售药局
• 医院药房
• 网路药局

第7章全球结节性痒疹治疗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
  亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 世界其他地区
  • 拉丁美洲
  • 中东和非洲

第 8 章 全球结节性痒疹治疗市场的竞争格局

• 概述
• 各公司的市场排名
• 主要发展策略

第9章 公司简介

• Bayer AG
• Galderma SA（Nestle Skin Health Company）
• Pfizer, Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• GlaxoSmithKline Plc
• VYNE Therapeutics, Inc.
• Trevi Therapeutics, Inc
• Merck & Co., Inc.
• Novartis AG
• Celgene Corporation
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson

第10章 附录

• 相关报告

Prurigo Nodularis Treatment Market Valuation - 2024-2031

The Prurigo Nodularis (PN) therapy market is developing in response to the condition's increasing prevalence and rising awareness among healthcare practitioners and patients. Prurigo nodularis is a persistent skin illness that causes itchy nodules and has a major impact on a patient's quality of life. Over the last decade, there has been an increase in the number of diagnosed cases, partially due to improved diagnostic procedures and increased recognition of the disorder by dermatologists and general practitioners by enabling the market to surpass a revenue of USD 1.30 Billion valued in 2024 and reach a valuation of around USD 1.90 Billion by 2031.

The increasing use of telemedicine and digital health platforms makes dermatological consultations and treatments more accessible which contributes to the growing demand for PN therapies. As a result, the PN treatment market is predicted to expand significantly driven by a combination of rising illness prevalence, therapeutic improvements, and improved patient access to healthcare services by enabling the market to grow at a CAGR of 5.30% from 2024 to 2031.

Prurigo Nodularis Treatment Market: Definition/ Overview

Prurigo nodularis (PN) is a chronic skin disorder distinguished by very irritating nodules that are frequently caused by persistent scratching and inflammation. Prurigo nodularis treatment focuses on symptom relief, itch management, and addressing underlying causes to enhance the patient's quality of life. Topical therapies are one of the most common methods for treating PN. Corticosteroids, calcineurin inhibitors, and capsaicin lotions are frequently used to treat inflammation and itching.

Prurigo nodularis (PN) is a persistent skin ailment that causes itchy nodules and has a major influence on a patient's quality of life. Prurigo nodularis is treated using a variety of techniques focused on symptom management, itch relief, and skin lesion improvement. Topical therapies are one of the most common applications for PN therapy. These include corticosteroids, calcineurin inhibitors, and capsaicin creams.

The future of PN management will most likely involve an integrated approach that combines pharmacological and non-pharmacological techniques. As more is learned about the psychological impact of PN, comprehensive treatment strategies that include behavioral therapy, stress management, and lifestyle changes are becoming more widely accepted.

Will Increasing Demand for Capsaicin Cream Influence the Product Segment?

The growing demand for capsaicin cream is a major driver in the prurigo nodularis treatment market, particularly within the product segment. Capsaicin, derived from chili peppers has shown promise in treating the severe itching associated with prurigo nodularis. The increasing prevalence of prurigo nodularis is a major driver of this demand. According to research published in the Journal of the American Academy of Dermatology, the estimated prevalence of PN in the United States is 72 instances per 100,000 individuals. This equates to roughly 230,000 people impacted by this illness in the United States alone. According to the National Eczema Association, PN affects around one in every 4,000 people in the general community demonstrating its widespread prevalence.

According to the National Center for Biotechnology Information (NCBI) in a clinical trial, 33% of patients receiving capsaicin cream reported a significant reduction in pruritus compared to only 7% in the placebo group. This illustrates capsaicin's potential usefulness in treating PN symptoms. Furthermore, the growing interest in natural and over-the-counter medicines is driving up the market for capsaicin cream. The American Academy of Dermatology points out that topical capsaicin is available without a prescription making it a viable alternative for many people.

Will Lack of Qualified Healthcare Professionals Hamper the Prurigo Nodularis Treatment Market?

The prurigo nodularis treatment market may be hampered by a lack of skilled healthcare practitioners, however, various factors may mitigate this potential barrier. One major factor is the rising global prevalence of prurigo nodularis (PN). While exact numbers are limited due to underdiagnosis, research indicates that PN affects roughly 72 per 100,000 persons in the United States. The increased frequency necessitates a greater demand for treatment choices and professionals. Furthermore, advances in diagnostic procedures are enhancing the detection of PN patients. For example, a 2022 study published in the Journal of the American Academy of Dermatology discovered that dermoscopy improved diagnostic accuracy for PN by 23% when compared to clinical examination alone.

This significant economic impact is expected to drive investment in treatment development and specialized training. Furthermore, the FDA's approval of dupilumab for PN therapy in 2022 has raised awareness and interest in this market area. According to the National Eczema Association, dupilumab showed a 60% reduction in itch severity in clinical studies, potentially enhancing the quality of life for many PN sufferers. While the scarcity of healthcare personnel remains a worry, several market factors may assist in offsetting its effects. Despite labor issues, increasing disease awareness, economic incentives, and treatment improvements should attract more specialists to the sector and drive market expansion. However, addressing the healthcare personnel deficit is critical to fully fulfilling the market's potential.

Category-Wise Acumens

Will Widespread Use and Trust in Corticosteroids Influence the Product Segment?

Corticosteroids dominate the market owing to their demonstrated usefulness in regulating inflammation and lowering itching caused by the illness. Dermatologists frequently prescribe corticosteroids as the first line of treatment. They are available in topical, oral, and injectable forms. They operate by inhibiting the immunological response that causes itchy nodules resulting in great alleviation for patients. Topical corticosteroids are especially popular because they may be applied directly to the afflicted areas providing localized treatment with less systemic adverse effects than oral or injectable alternatives. Corticosteroids' broad use and trust supported by multiple clinical research and decades of medical practice solidifies their dominance in the PN therapy market.

Corticosteroids' dominance in the PN therapy market is driven not only by their efficacy but also by their availability. These drugs are readily available and come in a variety of dosages and formulations making them appropriate for different stages and severity levels of PN. This flexibility enables healthcare providers to adjust treatment strategies to particular patient demands, hence improving treatment outcomes. Furthermore, corticosteroids are frequently covered by insurance programs which reduces patients' financial burden and encourages treatment adherence.

Will the Rising Preference for Medications Drive Growth in the Distribution Channel Segment?

The retail pharmacies category is expected to have the highest compound annual growth rate (CAGR) in the prurigo nodularis treatment market over the forecast period. This dominance is partly due to an increasing propensity for obtaining pharmaceuticals from retail pharmacies which is heavily affected by their accessibility and convenience. Retail pharmacies are frequently more accessible to patients than hospitals or online pharmacies as they have longer hours and are placed in convenient neighborhood locations. This makes them the first choice for many people who need fast relief from the symptoms of prurigo nodularis which can be quite uncomfortable and debilitating.

Retail pharmacies frequently offer numerous incentives to attract patients such as discounts and loyalty programs. These cost-cutting approaches are especially tempting to patients who need long-term treatment for chronic illnesses such as prurigo nodularis. The economic benefits provided by retail pharmacies can greatly lessen patient's financial burden encouraging them to continue their therapy uninterrupted. This is especially critical in the treatment of prurigo nodularis where strict adherence to prescribed medication regimens is required for successful symptom control and flare-up avoidance.

Country/Region-wise Acumens

Will the Rising Disease Awareness Drive the Growth in the Asia Pacific Region?

The Asia Pacific region is expected to see considerable growth in the Prurigo Nodularis (PN) treatment market owing to increase in illness awareness and improved healthcare infrastructure. As more people and healthcare providers become aware of the signs and effects of PN, there is a greater desire for effective treatments. According to research published in the Journal of the American Academy of Dermatology, the frequency of PN in Asia varies between 0.1% and 3.8% of the population depending on the country and demography. This incidence combined with the massive population bases in countries such as China and India indicates a significant potential market for PN treatments.

Organizations such as the International Forum for the Study of Itch (IFSI) and the Asian Academy of Dermatology and Venereology (AADV) have played an important role in educating both patients and healthcare professionals about PN contributing to the increase in disease awareness. According to World Health Organization (WHO) research, dermatological disorders including PN are becoming more widely recognized as serious health concerns in the Asia Pacific region with a 15% increase in reported cases in the last five years.

Will the Rising Healthcare Expenditures and a Growing Patient Population Boost the Market in the North American Region?

The prurigo nodularis (PN) treatment market in North America is expected to increase significantly owing to many main factors. One of the main drivers is the region's increase in healthcare expenses. According to the Centers for Medicare and Medicaid Services (CMS), U.S. healthcare spending will exceed USD 4.3 Trillion in 2021, up 2.7% from 2020. This trend of increase in healthcare spending is anticipated to continue with forecasts indicating that it would reach USD 6.2 Trillion by 2028. The significant investment in healthcare infrastructure and research creates an enabling environment for the development and implementation of novel PN treatments. Furthermore, the expanding patient population is a key driver of market expansion.

Another key cause is the growing awareness and diagnosis of PN. The National Eczema Association has been actively striving to increase awareness of PN and other associated disorders resulting in better recognition and diagnosis. This, together with developments in diagnostic procedures is expected to enhance the identified patient pool accelerating market expansion. The market also benefits from ongoing R&D initiatives. The National Institutes of Health (NIH) has financed various research on PN, and clinicaltrials.gov lists more than 20 active or recruiting clinical trials for PN treatments as of 2024. This extensive pipeline of prospective therapies is projected to provide more effective treatment alternatives, hence supporting market growth.

Competitive Landscape

The prurigo nodularis treatment market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the prurigo nodularis treatment market include:

Bayer AG

Galderma SA (Nestle Skin Health Company)

Pfizer, Inc.

Sanofi SA

Takeda Pharmaceutical Company Limited

GlaxoSmithKline Plc

VYNE Therapeutics, Inc.

Trevi Therapeutics, Inc

Merck & Co., Inc.

Novartis AG

Celgene Corporation

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson

Latest Developments

In February 2023, Pfizer is planning an unprecedented number of pharmaceutical launches with the corporation expected to release 19 new drugs over the next 18 months.

In June 2023, Novartis announced that it has agreed to acquire Chinook Therapeutics, a Seattle, WA-based clinical-stage biopharmaceutical company with two high-value, late-stage medicines in development for rare, severe chronic kidney diseases. The agreed-upon deal is subject to customary closing conditions and is fully consistent with Novartis' strategy to focus on innovative medicines. It will significantly expand its renal portfolio, complementing the existing pipeline.

Prurigo Nodularis Treatment Market, By Category

• Product:
• Antihistamines
• Capsaicin Cream
• Corticosteroids
• Emollients
• Others
• Distribution Channel:
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PRURIGO NODULARIS TREATMENT MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL PRURIGO NODULARIS TREATMENT MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Antihistamines
• 5.3 Capsacin Cream
• 5.4 Corticosteroids
• 5.5 Emollients
• 5.6 Others

6 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Retail Pharmacies
• 6.3 Hospital Pharmacies
• 6.4 Online Pharmacies

7 GLOBAL PRURIGO NODULARIS TREATMENT MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL PRURIGO NODULARIS TREATMENT MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Bayer AG
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Galderma SA (Nestle Skin Health Company)
• 9.3 Pfizer, Inc.
• 9.4 Sanofi SA
• 9.5 Takeda Pharmaceutical Company Limited
• 9.6 GlaxoSmithKline Plc
• 9.7 VYNE Therapeutics, Inc.
• 9.8 Trevi Therapeutics, Inc
• 9.9 Merck & Co., Inc.
• 9.10 Novartis AG
• 9.11 Celgene Corporation
• 9.12 Teva Pharmaceutical Industries Ltd.
• 9.13 Johnson & Johnson

10 Appendix

• 10.1 Related Research